sorafenib has been researched along with alsterpaullone in 5 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (alsterpaullone) | Trials (alsterpaullone) | Recent Studies (post-2010) (alsterpaullone) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 80 | 0 | 31 |
| Protein | Taxonomy | sorafenib (IC50) | alsterpaullone (IC50) |
|---|---|---|---|
| Chain A, Glycogen Synthase Kinase-3 Beta | Homo sapiens (human) | 0.004 | |
| Chain B, Glycogen Synthase Kinase-3 Beta | Homo sapiens (human) | 0.004 | |
| Chain A, Glycogen Synthase Kinase-3 Beta | Homo sapiens (human) | 0.004 | |
| G2/mitotic-specific cyclin-B2 | Homo sapiens (human) | 0.035 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.0321 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 1.5 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.035 | |
| G2/mitotic-specific cyclin-B | Marthasterias glacialis (spiny starfish) | 0.0263 | |
| Glycogen synthase kinase-3 beta | Rattus norvegicus (Norway rat) | 0.0263 | |
| Cyclin-A2 | Homo sapiens (human) | 0.015 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.015 | |
| Glycogen synthase kinase-3 alpha | Homo sapiens (human) | 0.0043 | |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | 0.0105 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.0608 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.0815 | |
| G2/mitotic-specific cyclin-B3 | Homo sapiens (human) | 0.035 | |
| Cyclin-dependent kinase 1 | Oryzias latipes (Japanese medaka) | 0.0263 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N | 1 |
| Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
| Caballero, E; García-Cárceles, J; Gil, C; Martínez, A | 1 |
| Laufer, S; Pillaiyar, T | 1 |
2 review(s) available for sorafenib and alsterpaullone
| Article | Year |
|---|---|
Kinase Inhibitors as Underexplored Antiviral Agents.
Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses | 2022 |
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Protein Kinase Inhibitors; SARS-CoV-2; Signal Transduction; Virus Replication | 2022 |
3 other study(ies) available for sorafenib and alsterpaullone
| Article | Year |
|---|---|
The selectivity of protein kinase inhibitors: a further update.
Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera | 2007 |
Navigating the kinome.
Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology | 2011 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |